Evidence map›Paper›PMID 33140122›Full record

Trial reportPharmaceutical research2020

Simultaneous Pharmacokinetic Analysis of Nitrate and its Reduced Metabolite, Nitrite, Following Ingestion of Inorganic Nitrate in a Mixed Patient Population.

Andrew R Coggan, Susan B Racette, Dakkota Thies, Linda R Peterson, Robert E Stratford

Abstract readClinical Trial, Phase IClinical Trial, Phase IIRandomized Controlled Trial
In one paragraph

Trial report in Pharmaceutical research, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Trial
  3. Trial
  4. Trial
  5. Trial
  6. Trial
  7. Article
  8. Review
  9. Article
  10. Review
  11. Review
  12. Article
  13. Article
  14. Article
  15. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Andrew R CogganDepartment of Kinesiology, Indiana University Purdue University, Indianapolis, Indiana, 46202, USA.
Susan B RacetteDepartment of Medicine, Washington University School of Medicine, St. Louis, Missouri, 63110, USA.
Dakkota ThiesDepartment of Medicine, Washington University School of Medicine, St. Louis, Missouri, 63110, USA.
Linda R PetersonDepartment of Medicine, Washington University School of Medicine, St. Louis, Missouri, 63110, USA.
Robert E StratfordDivision of Clinical Pharmacology, Department of Medicine, Research II, Indiana University School of Medicine, 950 West Walnut Street, Indianapolis, Indiana, 46202, USA. robstrat@iu.edu.ORCID http://orcid.org/0000-0002-9735-0220

Funding

WU INSTITUTE OF CLINICAL AND TRANSLATIONAL SCIENCESUL1TR002345 · NCATS · WASHINGTON UNIVERSITY · PI William G. Powderly · 2017 to 2026
$97.8M
Washington University Institute of Clinical and Translational SciencesUL1TR000448 · NCATS · WASHINGTON UNIVERSITY · PI EVANOFF, BRADLEY A · 2012 to 2016
$41.4M
Quality Assurance and Quality Control Project Management: Improving Submissions and Study Conduct in the Human Subjects Research Prior Approval ProcessUL1TR002529 · NCATS · INDIANA UNIVERSITY INDIANAPOLIS · PI MOE, SHARON M, WIEHE, SARAH ELIZABETH · 2018 to 2022
$27.2M
WU P&FP30DK020579 · NIDDK · WASHINGTON UNIVERSITY · PI Clay F. Semenkovich · 2013 to 2026
$27.1M
Resource CoreP30AR072581 · NIAMS · INDIANA UNIVERSITY INDIANAPOLIS · PI Sharon M Moe · 2017 to 2026
$8.3M
THE INORGANIC NITRATE FOR EXERCISE IN HEART FAILURE (INIX-HF) TRIALR34HL138253 · NHLBI · WASHINGTON UNIVERSITY · PI COGGAN, ANDREW R, PETERSON, LINDA RUTH · 2017 to 2019
$701k
Maximizing benefit and minimizing detriment of exercise for pulmonary hypertensionR15HL121661 · NHLBI · INDIANA UNIVERSITY INDIANAPOLIS · PI BROWN, MARY BETH · 2015 to 2015
$455k
Dietary Nitrate and Muscle Power with AgingR21AG053606 · NIA · INDIANA UNIVERSITY INDIANAPOLIS · PI COGGAN, ANDREW R · 2018 to 2019
$433k
NCATS NIH HHS UL1 TR000448NCATS NIH HHS UL1 TR000448 and UL1 TR002529NCATS NIH HHS UL1 TR002345NCATS NIH HHS UL1 TR002529NHLBI NIH HHS HL121661NHLBI NIH HHS R15 HL121661NHLBI NIH HHS R34 HL138253NIAMS NIH HHS AR072581NIAMS NIH HHS P30 AR072581NIA NIH HHS AG053606NIA NIH HHS R21 AG053606NIDDK NIH HHS P30 DK020579
6 · The paper itself

Abstract

purposeThe pharmacokinetic properties of plasma NO

methodsLinear and non-linear mixed effects analyses were used to statistically define concentration dependency on time, dose, as well as patient and study variables, and to integrate NO

resultsA population pharmacokinetic model relating NO

conclusionsExtension of the present first-generation model, to ultimately optimize NO

Indexed as

Dietary SupplementsModels, BiologicalAdministration, OralAgedAgingBiological AvailabilityBody WeightCross-Over StudiesFemaleHeart FailureHumansMaleNitratesNitritesRetrospective StudiesSarcopeniaNitratesNitritesisokinetic dynamometrynitrateNitric oxidenitritepharmacokinetics

Identifiers

PMID33140122
PMCPMC7719268

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.